Search Results

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.

As a leader in the field of research-based cardiorenal metabolic health education, CMHC is proud to partner with like-minded organizations such as the National Lipid Association, which offers its education-focused agenda to a wide number of lipid specialists representing all areas of the U.S.

The global lipid nanoparticles market revenue reached US$ 820.51 million in 2023 and is estimated to reach a market valuation of US$ 2,387.98 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.6% during the forecast period from 2024 to 2032.

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

NeuroBo Pharmaceuticals, Inc. announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models.

Global Lipid Nanoparticles (LNPs) CDMO Market in terms of revenue was predicted to be worth $182.0 Mn in 2023 and is poised to reach 518.2 Mn by 2031, increasing at a CAGR of 14.10% from 2024 to 2031.